Levy J H, Bailey J M
Division of Cardiothoracic Anesthesiology, Emory University School of Medicine, Emory University Hospital, Atlanta, GA 30322.
J Cardiothorac Anesth. 1989 Dec;3(6 Suppl 2):10-4. doi: 10.1016/0888-6296(89)90054-9.
Amrinone is a selective inhibitor of phosphodiesterase fraction 3 in both cardiac and smooth muscle. Intravenous administration in humans produces increased contractility and vasodilation of venous capacitance and arterial conductance vessels. The elimination half-life in healthy patients is reported to be 2.6 to 4.1 hours, making it the only long-acting positive inotropic agent available that can be administered either as an intravenous bolus or by infusion. A low incidence of side effects, often minor, has been reported with intravenous use. Thrombocytopenia does not seem to be a problem with short-term use. Amrinone represents a new approach in the pharmacologic therapy for ventricular dysfunction following cardiac surgery.
氨力农是一种对心肌和平滑肌中的磷酸二酯酶3具有选择性抑制作用的药物。在人体中静脉给药可增强心肌收缩力，并使静脉容量血管和动脉传导血管扩张。据报道，健康患者的消除半衰期为2.6至4.1小时，这使其成为唯一一种可通过静脉推注或静脉输注给药的长效正性肌力药物。静脉使用时，副作用发生率较低，且通常较轻微。短期使用似乎不会出现血小板减少问题。氨力农为心脏手术后心室功能障碍的药物治疗提供了一种新方法。
